Matches in SemOpenAlex for { <https://semopenalex.org/work/W2771636431> ?p ?o ?g. }
- W2771636431 endingPage "892" @default.
- W2771636431 startingPage "880" @default.
- W2771636431 abstract "BACKGROUND: Renal dysfunction is very common in patients with advanced liver cirrhosis and portal hypertension. The development of renal failure in the absence of clinical, anatomical or pathological causes renal of failure is termed hepatorenal syndrome (HRS).AIM: The present study was constructed to investigate the possible protective effects of nebivolol (Nebi) against D-galactosamine (Gal)-induced HRS in rats.MATERIAL AND METHODS: Rats were treated with Nebi for ten successive days. On the 8th day of the experiment, they received a single dose of Gal. Serum levels of Cr, BUN, Na+ and K+ as well as AST, ALT, total bilirubin (TB), NH3 and endothelin-1 (ET-1) were determined following Gal administration. Moreover, renal and liver contents of MDA, GSH, F2-isoprostanes (F2-IPs), tumor necrosis factor-alpha (TNF-α), nuclear factor kappa-B (NF-кB), total nitric oxide (NO), in addition to activities of caspase-3 (Cas-3), heme oxygenase-1 (HO-1), inducible and endothelial NO synthase (iNOS and eNOS) enzymes were also assessed. Finally, histopathological examination was performed.RESULTS: Nebi attenuated Gal-induced renal and hepatic dysfunction. It also decreased the Gal-induced oxidative stress and inflammatory recruitment.CONCLUSION: Results demonstrated both nephroprotective and hepatoprotective effects of Nebi against HRS and suggested a role of its antioxidant, anti-inflammatory, anti-apoptotic and NO-releasing properties." @default.
- W2771636431 created "2017-12-22" @default.
- W2771636431 creator A5009554993 @default.
- W2771636431 creator A5012342055 @default.
- W2771636431 creator A5040352583 @default.
- W2771636431 creator A5051015327 @default.
- W2771636431 creator A5074072600 @default.
- W2771636431 date "2017-12-13" @default.
- W2771636431 modified "2023-09-30" @default.
- W2771636431 title "Protective Effects of the Third Generation Vasodilatory Βeta - Blocker Nebivolol against D-Galactosamine - Induced Hepatorenal Syndrome in Rats" @default.
- W2771636431 cites W143899296 @default.
- W2771636431 cites W1520014993 @default.
- W2771636431 cites W1544316290 @default.
- W2771636431 cites W1910564505 @default.
- W2771636431 cites W1931349869 @default.
- W2771636431 cites W1957784724 @default.
- W2771636431 cites W1972983748 @default.
- W2771636431 cites W1973141265 @default.
- W2771636431 cites W1973887423 @default.
- W2771636431 cites W1977356230 @default.
- W2771636431 cites W1978314464 @default.
- W2771636431 cites W1978714593 @default.
- W2771636431 cites W1981165639 @default.
- W2771636431 cites W1984419141 @default.
- W2771636431 cites W1984927802 @default.
- W2771636431 cites W1987707042 @default.
- W2771636431 cites W1990341410 @default.
- W2771636431 cites W1997661628 @default.
- W2771636431 cites W1999703365 @default.
- W2771636431 cites W2005911802 @default.
- W2771636431 cites W2007955652 @default.
- W2771636431 cites W2008914711 @default.
- W2771636431 cites W2010307719 @default.
- W2771636431 cites W2011052049 @default.
- W2771636431 cites W2015019389 @default.
- W2771636431 cites W2016778253 @default.
- W2771636431 cites W2018124968 @default.
- W2771636431 cites W2018344800 @default.
- W2771636431 cites W2021447545 @default.
- W2771636431 cites W2021465634 @default.
- W2771636431 cites W2021578867 @default.
- W2771636431 cites W2031247740 @default.
- W2771636431 cites W2033190495 @default.
- W2771636431 cites W2040602146 @default.
- W2771636431 cites W2047273078 @default.
- W2771636431 cites W2047485746 @default.
- W2771636431 cites W2050056190 @default.
- W2771636431 cites W2052059735 @default.
- W2771636431 cites W2059110340 @default.
- W2771636431 cites W2065310067 @default.
- W2771636431 cites W2067003956 @default.
- W2771636431 cites W2069357664 @default.
- W2771636431 cites W2071022372 @default.
- W2771636431 cites W2074825927 @default.
- W2771636431 cites W2075611530 @default.
- W2771636431 cites W2080308468 @default.
- W2771636431 cites W2080418607 @default.
- W2771636431 cites W2080558596 @default.
- W2771636431 cites W2080898971 @default.
- W2771636431 cites W2086546660 @default.
- W2771636431 cites W2087516645 @default.
- W2771636431 cites W2091608449 @default.
- W2771636431 cites W2104359367 @default.
- W2771636431 cites W2113763357 @default.
- W2771636431 cites W2116541428 @default.
- W2771636431 cites W2118550481 @default.
- W2771636431 cites W2128500255 @default.
- W2771636431 cites W2129681910 @default.
- W2771636431 cites W2137956638 @default.
- W2771636431 cites W2148951514 @default.
- W2771636431 cites W2149396121 @default.
- W2771636431 cites W2151980275 @default.
- W2771636431 cites W2159950962 @default.
- W2771636431 cites W2160711898 @default.
- W2771636431 cites W2165859264 @default.
- W2771636431 cites W2167003284 @default.
- W2771636431 cites W2168745399 @default.
- W2771636431 cites W2171362910 @default.
- W2771636431 cites W2177291250 @default.
- W2771636431 cites W2190031201 @default.
- W2771636431 cites W2226991433 @default.
- W2771636431 cites W2230789306 @default.
- W2771636431 cites W2320516100 @default.
- W2771636431 cites W2338255346 @default.
- W2771636431 cites W2339760129 @default.
- W2771636431 cites W2343313313 @default.
- W2771636431 cites W2401833325 @default.
- W2771636431 cites W2402002018 @default.
- W2771636431 cites W2415183088 @default.
- W2771636431 cites W2415325831 @default.
- W2771636431 cites W2472314216 @default.
- W2771636431 cites W2483337407 @default.
- W2771636431 cites W25212373 @default.
- W2771636431 cites W2553739921 @default.
- W2771636431 cites W2564253771 @default.
- W2771636431 cites W262072234 @default.
- W2771636431 doi "https://doi.org/10.3889/oamjms.2017.173" @default.
- W2771636431 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5771289" @default.